CSTB

Across TCGA pan-cancer cohorts, CSTB Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CSTB data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CSTB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CSTB expression acts as an unfavorable survival marker.

MESO are the cancer types where CSTB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

CSTB–MESO (DFS)

Open the MESO breakdown →